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Background: Bronchodilator medications are central to the symptomatic management of chronic obstructive
pulmonary disease (COPD). Metered-dose inhalers (MDIs) are the most commonly used devices to deliver treatment
to patients with COPD and asthma, comprising approximately 70% of bronchodilator prescriptions. Proprietary
porous-particle technology permits the formulation of long-acting muscarinic antagonists, long-acting β2-agonists,
and a combination of both in hydrofluoroalkane (HFA) MDIs, providing a solution to formulation challenges
inherent to the development of HFA MDIs, which have contributed to the development of dry-powder inhalers.
Methods: In this randomized, double-blind, 4-period, 6-treatment, placebo- and active-controlled, multicenter,
crossover study, 4 ascending single doses of a proprietary glycopyrronium (GP) MDI were evaluated compared with
Placebo MDI and open-label tiotropium (TIO) in study patients with COPD. Thirty-three study patients were enrolled
and received single-dose administration of 4 of the 6 treatments (Placebo MDI, TIO 18 μg, or GP MDI at 14.4, 28.8,
57.6, and 115.2 μg ex-actuator) with an interval of 1 to 3 weeks between doses. The primary efficacy endpoint was
peak change in forced expiratory volume in 1 second (FEV1).
Results: All 4 doses of GP MDI showed statistically superior efficacy compared with Placebo MDI for peak FEV1
(differences of 146 to 248 mL; P < .001), with a clear dose ordering of the response. Statistically significant
differences compared with Placebo MDI were noted at almost all doses for the secondary FEV1 parameters
(P≤ .049) except 24-hour trough FEV1 at 28.8 μg. All doses were safe and well tolerated in this study; the most
frequently reported adverse event was dry mouth (0–14.3% across doses; 9.5% for Placebo MDI, and 9.1% for TIO).
Conclusions: This study demonstrated superior bronchodilatory efficacy of GP MDI compared with Placebo MDI at
all doses tested, and no serious adverse events were reported. This study supports the further evaluation of GP MDI
in study patients with COPD. In addition, these findings indicate that the correct dosage of glycopyrronium is no
more than 115.2 μg total daily dose, or 57.6 μg twice daily based on comparisons with the active comparator.
Trial registration: This clinical trial was registered on ClinicalTrials.gov, Identifier: NCT00871182.
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Bronchodilator medications are central to the symp-
tomatic management of chronic obstructive pulmonary
disease (COPD) [1]. Inhaled short- and long-acting mus-
carinic antagonists (SAMAs and LAMAs), such as ipra-
tropium and tiotropium bromide, respectively, are among
the main classes of bronchodilators used for the treatment
of COPD and have been shown to improve lung function
and reduce COPD symptoms [2]. Metered-dose inhalers
(MDIs) are the most commonly used devices to deliver
treatment to patients with COPD and asthma, comprising
approximately 70% of bronchodilator prescriptions [2,3].
Although they are easy to use and are well-accepted, ef-
forts to comply with federal laws mandating the phasing-
out of chlorofluorocarbon propellants have encountered
technical barriers in the creation of a stable formulation,
which have led several companies to instead pursue the
commercialization of dry-powder inhalers (DPIs).
Hollow, porous-particles added to HFA MDIs provide a
mechanism for stabilizing suspensions of inhaled drugs,
leading to improved physical stability, ability to formulate
very low doses, consistent dose-to-dose performance, and
high fine-particle fraction (FPF) [4,5]. The large area of
the hollow, porous particles allows therapeutic agents to
be adsorbed and delivered into the lungs during in-
halation. The particles themselves are comprised of dis-
tearoyl-phosphatidylcholine (DSPC), a naturally occurring
lung surfactant that is used frequently in approved
pharmaceutical preparations, and CaCl2. The initial ex-
ploration of these respirable porous particles as a delivery
platform for inhaled bronchodilator therapy was per-
formed with formoterol as a monotherapy. Another ad-
vantage offered by the porous-particle technology includes
relatively uniform aerodynamic particle size distribution
allowing delivery of drug to the lower respiratory tract
[4-7] with minimized oropharyngeal exposure.
Glycopyrronium (GP) is an antimuscarinic drug that has
been approved by the U.S. Food and Drug Administration
for systemic administration in multiple clinical scenarios,
including as a preoperative agent to reduce the volume of
saliva and acidity of gastric secretions [8,9]. It is a quater-
nary ammonium derivative that when inhaled results in
minimal mucosal absorption and systemic side effects
[10,11]. A dry-powder inhalation formulation of glyco-
pyrronium recently approved in Europe and Japan has
demonstrated significant and sustained bronchodilator ef-
ficacy over a 24-hour period as well as a positive safety
and tolerability profile [12,13].
The present study represents the first clinical study of a
glycopyrronium metered-dose inhaler (GP MDI) developed
using a proprietary lipid-based porous-particle. This study
was designed to evaluate the efficacy and safety of 4 doses
of GP MDI to serve as the basis for selecting the dose(s)
that produce a consistent 12- and/or 24-hour duration ofaction for more definitive studies. Tiotropium bromide
18 μg [(Spiriva® delivered via the Handihaler®; Boehringer
Ingelheim Pharmaceuticals, Ridgefield, Connecticut)(TIO)]
[14] was included as an open-label active comparator.Methods
This was a randomized, double-blind, 4-period, 6-treat-
ment, placebo- and active-controlled, incomplete block,
crossover, multicenter study to evaluate the single admin-
istration of 4 ascending single doses of GP MDI compared
with Placebo MDI and TIO as an active control in study
patients with COPD, and was conducted between March,
2009 and September, 2009. The particles administered by
this device have a mean aerodynamic diameter of 3.5 μm
(GP MDI 14.4 μg in monotherapy) [5]. It should be noted
that Pearl Therapeutics has recently revised the nomen-
clature for GP MDI to refer to the active moiety, glyco-
pyrronium, rather than the bromide salt form previously
referred to as glycopyrronium bromide (also known as
glycopyrrolate). The doses tested in the current study are
equivalent to 115.2, 57.6, 28.8 and 14.4 μg of glycopyrro-
nium. This change does not reflect a change to the formu-
lation of GP MDI, only in the expression of the strength/
dose. To aid in the selection of doses for further deve-
lopment, a marketed open-label active comparator was in-
cluded in this study (TIO).
The conduct of this study (PT0010801) complies with
the Declaration of Helsinki, and approvals were obtained
through an accredited Institutional Review Board (Inde-
pendent IRB, Plantation, FL, USA). Written informed
consent was obtained from each study patient prior to
entry into the trial. The study was listed on all appro-
priate clinical trial registries, including the United States
(US) National Institutes of Health’s ClinicalTrials.gov
(NCT00871182).Study patients
Eligible patients were 40 to 75 years of age with an estab-
lished clinical history of COPD; current or prior history of
at least 10 pack-years of cigarette smoking; measured
post-ipratropium forced expiratory volume in 1 second
(FEV1)/forced vital capacity (FVC) ratio of ≤0.70; mea-
sured post-ipratropium FEV1 ≥ 50% and ≤85% of predicted
normal values; and demonstrated reversibility to ipratro-
pium (>200 mL improvement and/or >12% and >150 mL
improvement from baseline FEV1 30 minutes following
administration of 4 puffs of ipratropium).
Key exclusion criteria were a primary diagnosis of
asthma, history of significant diseases other than COPD,
acute worsening of COPD that required treatment within
6 weeks prior to screening or between the screening
and baseline visits, symptomatic prostatic hypertrophy or
bladder neck obstruction, known narrow-angle glaucoma,
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cardiogram (ECG) abnormalities.
Study patients meeting the entry criteria who were ta-
king certain COPD medications at screening (TIO, oral
β2-agonists, long-acting β2-agonists [LABAs], combination
corticosteroid/LABA products, theophylline, leukotriene
inhibitors [zafirlukast, montelukast, zileuton], or cromo-
glycate and/or nedocromil) discontinued these medica-
tions for the duration of the trial and were switched to
short-acting bronchodilators (ipratropium, albuterol, or
ipratropium/albuterol combination), with or without an
inhaled corticosteroid. During the study, 3.1% (n = 1) of
study subjects were using concomitant inhaled corticoste-
roids. Patients that were not taking any of the COPD
medications, and were previously maintained on albuterol,
ipratropium or a combination thereof, with or without an
inhaled corticosteroid (ICS) for at least one week prior to
screening (Visit 1a), were permitted to proceed directly to
Visit 2, providing they met all entry criteria. Study patients
previously treated with a maintenance dose of an ICS that
was not administered as a fixed dose combination together
with a LABA were permitted to continue the ICS, provid-
ing the daily dose did not exceed 1,000 μg of fluticasone or
equivalent, and they had been maintained on a stable dose
for at least 2 weeks.
To ensure that study patients were stable on the re-
vised treatment regimen, they were required to return
for a second screening visit at least 1 week but not lon-
ger than 3 weeks after altering maintenance medication.
Study patients were required to withhold all COPD
medications (including inhaled corticosteroids) for at
least 6 hours before the baseline visit and all subsequent
study treatment visits.
At Visit 2, study patients were randomized to 1 of 6 pos-
sible treatment sequences. Each sequence included single
administration of 4 of the 6 treatments evaluated in the
study: GP MDI at 14.4, 28.8, 57.6, and 115.2 μg ex-
actuator, Placebo MDI, and TIO 18 μg (active compara-
tor). Each sequence included 2 or 3 GP MDI doses, ad-
ministered in ascending order with a randomized position
of TIO and/or Placebo MDI in the sequence. Patients
returned to the clinic for treatment at Visits 3, 4, and 5
and for the final visit (Visit 6; approximately 1 week after
Visit 5). There was a washout interval between doses of at
least 1 week and no more than 3 weeks.
Study assessments and variables
On each of the 4 study drug dosing visits, spirometry was
conducted 60 and 30 minutes prior to study drug admi-
nistration; the average of these 2 assessments was used to
establish test-day baseline FEV1. Spirometry was obtained
at 15 and 30 minutes, and 1, 2, 4, 6, 8, 10, 12, 16, 22, 23,
and 24 hours post-dosing. The primary efficacy endpoint
was peak improvement in FEV1 relative to test-daybaseline, which was compared for each dose of GP MDI
relative to Placebo MDI. The secondary efficacy endpoints
included FEV1 area under the curve (AUC) for the 12, 24,
and 12- to 24-hour periods post-dosing relative to test-day
baseline: FEV1 AUC0-12, FEV1 AUC0–24, and FEV1
AUC12–24, trough FEV1 (tFEV1), and the time to onset of
action (≥10% improvement in mean FEV1 from test-day
baseline). Trough FEV1 at 24 hours is defined as the mean
of the FEV1 assessments taken at 23 and 24 hours post-
study drug administration. AUC values were normalized
in order to provide results in liter (L) units by dividing by
the length of time included in each interval. Pharmacoki-
netic (PK) sampling was performed at each treatment visit
and was conducted at specified time points up to 24 hours
post-dose. Safety analyses included adverse events (AEs)
and serious adverse events (SAEs), hematology and che-
mistry laboratory assessments, ECGs, vital signs, and
monitoring for paradoxical bronchospasm and symptoms
of dry mouth.
Statistical analyses
Published data suggest that it is reasonable to expect a
difference between investigational doses and placebo in
peak FEV1 that will exceed 0.15 L. Thus, if the within-
patient standard deviation does not exceed 0.20 L there
will be at least 80% power with N = 16 for the pairwise
comparisons [15]. The primary efficacy analyses were
the estimation of the pairwise differences along with
95% two-sided confidence intervals (CIs) for each GP
MDI dose vs Placebo MDI. Contrasts were estimated
using mixed-model analysis of variance for repeated
measures (MMRM) with subject as a random effect. A
Wilcoxon rank sum test was used to assess differences
in time-to-onset of effect.
Multiplicity was controlled for the primary endpoint
by a sequential procedure where GP MDI 115.2 μg was
first compared with Placebo MDI using a two-sided
alpha level of 5%. If this was significant, then GP MDI
57.6 μg was compared with Placebo MDI using the same
alpha level. This sequential testing approach was con-
tinued for comparisons of lower doses with Placebo
MDI in descending order. In addition, there was a linear
test of trend for the dose response that was prespecified
to be interpreted inferentially only if GP MDI 115.2 μg
was significant compared with Placebo MDI. There were
no further adjustments for multiple comparisons and
nominal significance is reported for all other compari-
sons based on two-sided P values < .05.
PK parameters were derived from the glycopyrronium
concentration-time data. Plasma PK parameters of gly-
copyrronium were calculated using non-compartmental
models. Concentrations below the limit of quantitation
were set to zero. Descriptive statistics were reported for
each PK parameter.
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Disposition and baseline characteristics
A total of 73 subjects were screened for the study. Of
these 25 (34.2%) were not eligible because of the rever-
sibility criteria. Of those eligible, 33 study patients were
enrolled in this study (Figure 1). No patients meeting
the entry criteria were taking leukotriene inhibitors
(zafirlukast, montelukast, zileuton) or cromoglycate and
nedocromil. Two study patients were withdrawn due to
rescue medication use during a test day. The majority of
study patients were male (58%) and Caucasian (97%).
Other demographic and baseline clinical characteristics
are shown in Table 1. The intent-to-treat/safety po-
pulation (N = 33) included all study patients who were
randomized and received at least one dose of study
treatment and was used for demographic and safety
analyses. A modified intent-to-treat (mITT) population
(n = 30) that excluded 3 randomized study patients due
to protocol violations (rescue medication use) was used
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PBO, placebo; TIO, tiotropium 
Figure 1 Study patient disposition; reports the overall enrollment, all
excluded for both failed FEV1 reversibility and a failed ECG, making the totaEfficacy
Primary efficacy variable
The mean change in FEV1 from test-day baseline over
time is illustrated in Figure 2. All 4 doses of GP MDI
demonstrated statistically superior efficacy compared with
Placebo MDI (P < 0.001) for peak change in FEV1
(Table 2). There was a clear dose ordering of the peak
FEV1 response, with the 115.2 μg dose presenting the
greatest difference from placebo (248 mL). TIO 18 μg also
demonstrated statistically superior efficacy compared with
Placebo MDI (P < 0.001) for peak change in FEV1.
Secondary efficacy variables
Each of the GP MDI doses exhibited a statistically signifi-
cantly greater (P ≤ 0.049) mean change from test-day base-
line compared with Placebo MDI for 12- and 24-hour
tFEV1, FEV1 AUC0-12, FEV1 AUC0–24, and FEV1 AUC12–24,
with the single exception of the GP MDI 28.8 μg compa-
rison for the 24-hour tFEV1 (P = 0.059) (Figure 3). GP MDI
demonstrated a more rapid onset of action compared withy
Screen Failures (n=40) 
ns, n (%):
d spirometry entry criteria, 11 (15.1) 
d FEV1 Reversibility, 25 (34.2) 
d ECG, 5 (6.8) 









edication use, 2 (6.1) 
ocation, and follow-up for study patients. Two patients were
l number of patients who failed screening 40.
Table 1 Demographic and baseline characteristics
(safety population)
Characteristics N = 33
Race, n (%)
Caucasian 32 (97%)




Mean (SD) 59.0 (6.7)
Median (Range) 58.1 (44–71)
Smoking Status, n (%)
Current Smoker 18 (55%)
Years Ago Quit, n 15
Mean (SD) 10.2 (7.7)
Median (Range) 9.5 (0–27)
Number of Years Smoked
Mean (SD) 38.6 (10.5)
Median (Range) 40.0 (13–57)
FEV1, L/sec, prebronchodilator
Mean (SD) 1.6 (0.5)
Median (Range) 1.5 (0.9–3.0)
FEV1, % predicted, prebronchodilator
Mean (SD) 50.5 (9.9)
Median (Range) 47.3 (35.5–69.3)
FEV1, % predicted, postbronchodilator
Mean (SD) 60.6 (10.3)
Median (Range) 57.6 (43.0–80.5)
FEV1 = forced expiratory volume in 1 second; SD = standard deviation; L=liter.
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FEV1 of 0.5 hours or less for all doses of GP MDI eva-
luated, compared with approximately 1 hour for TIO
18 μg.
PK
Mean plasma glycopyrronium concentrations over time
are presented in Figure 4. Overall, exposure (both maxi-
mum plasma concentration [Cmax] and AUC) increased in
a proportional manner with dose (Table 3). Cmax was
reached rapidly (usually within 6 minutes of dosing).
Apparent oral clearance and volume of distribution ap-
peared relatively consistent across doses.
Safety
The most frequently reported AE was dry mouth
(Table 4). All other AEs were reported only once or
twice during the study and were distributed across the
treatments. Dry mouth was also the most frequently re-
ported drug-related AE. The only other AEs besides drymouth reported as being drug-related were dyspnea
(GP MDI 28.8 μg, 1 study patient) and paradoxical
bronchospasm, defined as a reduction in FEV1 of >20%
from test-day baseline with associated symptoms of
wheezing, shortness of breath or cough (GP MDI
115.2 μg, 1 patient; mild in severity on the day following
treatment). No patient experienced an SAE during the
study, and no study patient discontinued due to an AE.
Changes in hematology, clinical chemistry, vital signs,
physical examination findings, and ECGs were small,
and no treatment-related trends were observed.
Discussion
The current study assessed GP administered by an MDI
using a proprietary lipid-based porous-particle. The FEV1
data obtained during this study indicate that a single-dose
of GP MDI yields statistically significant, dose-dependent,
and clinically relevant bronchodilation at all doses com-
pared with Placebo MDI. In terms of peak improvement
in FEV1, the efficacy of GP MDI 57.6 and 115.2 μg brac-
keted that of TIO 18 μg. Although both GP MDI 14.4 and
28.8 μg demonstrated clinically relevant and statistically
significant peak improvement in FEV1 compared with
Placebo MDI, the magnitude of these improvements was
numerically lower than those observed with TIO 18 μg.
The primary efficacy results are corroborated by the
secondary efficacy variables: 12- and 24-hour post-dose
FEV1, FEV1 AUC0-12, FEV1 AUC0–24, and FEV1 AUC12–24,
with statistically significant greater mean changes from
test-day baseline compared with Placebo MDI for all
comparisons, with the exception of GP MDI 28.8 μg for
24-hour post-dose FEV1. Point-estimates for the majority
of FEV1 parameters for GP MDI 57.6 and 115.2 μg were
within ± 50 mL compared with TIO. All GP MDI doses
demonstrated a rapid onset of action, and the 115.2 μg
dose demonstrated a significantly faster onset than TIO
18 μg. With regard to the duration of action of GP MDI,
several observations confirm that GP MDI is appropriate
for twice daily (BID) dosing. For all GP MDI doses, the
changes from baseline in FEV1 compared to Placebo MDI
at 12 hours post-dose were appreciably greater than the
changes at 24 hour post-dose, while these values were
more consistent for TIO compared to Placebo MDI. Simi-
larly, FEV1 AUC0–12 was greater than FEV1 AUC12–24 for
all GP doses compared with Placebo MDI, while for TIO
the difference from Placebo MDI in FEV1 AUC main-
tained close to 1:1 ratio across the 0- to 12- and 12- to
24-hour intervals. All doses of GP MDI were safe and well
tolerated. The most frequently reported AE was dry
mouth, which was reported for a similar proportion of
study patients following Placebo MDI, GP MDI, and TIO
(0–14.3% of patients).
Placing the data from the current study into context






































FEV1=forced expiratory volume in 1 second; GP MDI=glycopyrronium metered-dose inhaler; Tio=tiotropium.
GP MDI 14.4 µg
Placebo MDI 
GP MDI 28.8 µg
GP MDI 57.6 µg
GP MDI 115.2 µg
TIO 18 µg
Figure 2 Mean (±standard error) change from baseline in FEV1 over 24 hours by treatment; represents the results for the peak change
in FEV1 (the primary efficacy endpoint) as well as the change in FEV1 from test-day baseline over time.
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Breezehaler®, Novartis Europharm Limited, Horsham,
West Sussex, United Kingdom) in doses of 25, 40, 100,
and 200 μg found that the median time to reach maximal
plasma concentration (tmax) was similar between NVA237
(5–6.5 minutes post-inhalation) [16], to the 6 minutes for
GP MDI 28.8 to 115.2 μg observed in the current study.
The mean terminal elimination half-life (t1/2) of NVA237
is reported to range between 13 and 22 hours [16] com-
pared with 6.3 to 9.6 hours for GP MDI 28.8 to 115.2 μg.
It remains subject to debate whether these PK traits are
generalizable to specific benefits in lung function which
favor once-daily (QD) or BID dosing.Table 2 Mean peak change from baseline FEV1 (L) by treatme
PBO MDI GP MDI 14.4 μg GP MDI
Peak Change 0.182 0.328 0.3
Comparison vs PBO
Contrast Differencea N/A 0.146 0.1
SE N/A 0.040 0.0
90% CI N/A 0.066, 0.225 0.081,
Pb N/A <0.001 <0.0
aContrast difference [Treatment 1-Treatment 2]; bP from mixed-model analysis of va
CI = confidence interval; FEV1 = forced expiratory volume in 1 second; GP MDI = glyc
mITT =modified intent-to-treat; N/A = not applicable; PBO MDI = placebo metered-dIn comparing the efficacy of GP MDI observed in the
current study with that of NVA 237 50 μg administered
QD in the Glycopyrronium bromide in COPD airWays
clinical Study 1 (GLOW1) trial; treatment with NVA237
resulted in an improvement in 24-hr post dose FEV1
(average of mean 23 hours 15 minutes, and 23 hours
45 minutes post-dose values) of 105 mL after initial dosing
compared with placebo (P < .001) [17]. In the GLOW2
study [18], study patients received either NVA 237 50 μg,
TIO 18 μg or placebo once-daily (QD), the differences
from placebo in 24-hr post-dose FEV1 after initial dosing
were 91 and 83 mL for NVA 237 and TIO, respectively.
For the current study, GP MDI 115.2, 57.6, 28.8, andnt compared with placebo (mITT population)
28.8 μg GP MDI 57.6 μg GP MDI 115.2 μg TIO 18 μg
40 0.362 0.430 0.380
58 0.180 0.248 0.198
39 0.039 0.040 0.040
0.235 0.103, 0.257 0.168, 0.327 0.119, 0.278
01 <0.001 <0.001 <0.001
riance.
opyrronium metered-dose inhaler; L = liters;
ose inhaler; SE = standard error; TIO = tiotropium.
Peak
AUCx-y=area under the forced expiratory volume in 1 second curve from time x to time y post study-drug; 








12 hr Post-dose AUC0-12 24 hr Post-dose
P<0.05 for all comparisons with
placebo except 24 hr Post-dose
FEV1 for GP MDI 36 µg.
AUC0-24 AUC12-24




































Figure 3 Adjusted Mean (±standard error) change from baseline in FEV1 parameters relative to placebo; provides a concise depiction
of the mean change from baseline in peak FEV1, 12-hour FEV1, FEV1 AUC0–12, 24 hour FEV1, FEV1 AUC0–24, FEV1 AUC12–24.
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FEV1 compared with placebo of 133, 127, 68, and 74 mL,
respectively (P < .05). The 12-hour post-dose FEV1 for GP
MDI 115.2, 57.6, 28.8, and 14.4 μg BID in the current
study compared with placebo was 233, 157, 160, and
143 mL, respectively (all P < .001). It should be noted that
in the current study, the screening post-bronchodilator0 2 4 6 8 10
Tim




































Figure 4 Mean plasma glycopyrronium concentrations over time.percentage predicted FEV1 was 60.6% compared with 54%
for GLOW1 and 56% for GLOW2. Such patients may be
expected to demonstrate a greater post-bronchodilator re-
sponse. Of further note, since subjects in the current study
were required to be reversible, while most groups of
COPD patients benefit clinically by typical LAMAs [1],
subgroup data for QD umeclidinium suggest that subjects12
e (hours)
14 16 18 20 22 24
GP MDI 14.4 µg
GP MDI 28.8 µg
GP MDI 57.6 µg
GP MDI 115.2 µg
Table 3 Summary of glycopyrronium pharmacokinetic parameters (mITT population)
Parameter Arithmetic mean (CV%)
GP MDI 14.4 μg GP MDI 28.4 μg GP MDI 57.6 μg GP MDI 115.2 μg
N 18 18 20 20
AUC0–24 (pg•h/mL) 34.5 (101.2) 120 (67.2) 202 (74.5) 498 (82.0)
AUC0–12 (pg•h/mL) 31.9 (88.8) 89.9 (57.7) 163 (70.6) 398 (79.8)
AUC12–24 (pg•h/mL) 4.34 (250.5)
b 32.0 (147.0)d 41.0 (91.3)e 102 (100.9)f
AUC0-tlast (pg•h/mL) 30.7 (112.5) 113 (74.4) 196 (78.8) 491 (84.4)
AUC0-inf (pg•h/mL) 66.2 (72.2)
c 127 (68.7)b 252 (70.8)e 598 (84.0)f
Cmax (pg/mL) 15.6 (72.0) 27.3 (51.5) 62.9 (72.3) 160 (73.8)
tmax
a (h) 0.333 (0.0330, 0.350) 0.100 (0.0330, 0.383) 0.100 (0.0330, 0.917) 0.100 (0.0330, 0.933)
t1/2 (h) 5.09 (82.0)
c 6.28 (62.6)b 8.76 (59.4)e 9.61 (36.6)f
CL/F (L/h) 416 (77.0)c 494 (89.6)b 510 (81.3)e 422 (75.6)f
Vz/F (L) 1995 (32.2)c 3320 (56.9)b 4627 (50.9)e 4697 (49.7)f
aMedian (Min, Max); bn = 11; cn = 10; dn = 12; en = 19; fn = 16.
AUCx-y = area under the concentration-time curve from time x to time y; CL/F = apparent oral clearance; Cmax = maximum plasma concentration; CV% = coefficient
of variation; GP MDI = glycopyrronium metered-dose inhaler; t1/2 = apparent terminal elimination half-life; tmax = time to maximum concentration; Vz/F = apparent
volume of distribution; mITT=modified intention to treat.
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demonstrate somewhat greater FEV1 responses to treat-
ment with LAMA [19].
In the GLOW2 study, for FEV1 AUC0–12 on Day 1, the
difference from placebo for NVA237 was 159 mL,
32 mL above TIO [18], whereas in the current study theTable 4 Number (%) of study patients reporting AEs (safety p
Preferred term PBO MDI GP MDI
n = 21 14.4 μg
n (%) n = 21
n (%)
One or more AEs 4 (19.0) 3 (14.3)
Dry mouth 2 (9.5) 1 (4.8)
Oropharyngeal pain 0 1 (4.8)
Bronchospasm paradoxical 0 0
Nasopharyngitis 0 0
Urinary tract infection 0 0






Dizziness 0 1 (4.8)
Cough 0 1 (4.8)
Diarrhea 0 0
Umbilical hernia 1 (4.8) 0
Gastroenteritis 1 (4.8) 0
Gastrointestinal viral infection 1 (4.8) 0
AE = adverse event; DPI = dry powder inhaler GP MDI=glycopyrronium metered-dosdifference from Placebo MDI for GP MDI was 208, 155,
137, and 109 mL for 115.2, 57.6, 28.8, and 14.4 μg, re-
spectively, in comparison to 172 mL for TIO. Also in
GLOW2, the Day 1 improvement in peak FEV1 for NVA
237 compared to placebo was 200 mL, 47 mL greater
than TIO. Whereas in the current study, the peakopulation)
GP MDI GP MDI GP MDI TIO
28.8 μg 57.6 μg 115.2 μg 18 μg
n = 23 n = 21 n = 21 n = 22
n (%) n (%) n (%) n (%)
3 (13.0) 5 (23.8) 3 (14.3) 4 (18.2)
0 3 (14.3) 1 (4.8) 2 (9.1)
0 0 1 (4.8) 0
0 0 1 (4.8) 0
0 1 (4.8) 0 0
0 1 (4.8) 0 0
1 (4.3) 0 0 1 (4.5)
1 (4.3) 0 0 0
1 (4.3) 0 0 0
1 (4.3) 0 0 0
1 (4.3) 0 0 0
1 (4.3) 0 0 0
0 0 0 0
0 0 0 0
0 0 0 1 (4.5)
0 0 0 0
0 0 0 0
0 0 0 0
e inhaler; PBO = placebo; TIO = tiotropium.
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pared to Placebo MDI was 248, 180, 158, and 146 mL
for 115.2, 57.6, 28.8, and 14.4 μg, respectively, in com-
parison with 198 mL for TIO.
Twice-daily dosing is of particular interest for a com-
panion combination product containing glycopyrronium
and the LABA formoterol fumarate, which is currently in
development using the same porous-particle–based MDI
technology. The use of a LAMA in combination with a
LABA has been advocated in patients with COPD as
airflow obstruction becomes more severe [20-22]. As a
co-suspension platform, the porous-particle technology
produces efficient and stable single, dual, and triple com-
bination MDIs without a coformulation induced change
in aerosol performance across product types.
Study limitations
This study was conducted in COPD patients with de-
monstrated reversibility to a SAMA. Reversibility in a
COPD population is variable. Many “non-reversible” pa-
tients will experience effects of smaller magnitude, but
may still benefit; therefore, results should be confirmed in
a broader COPD population. The study assessed the dose
response following single dose administration across a
wide range of GP MDI doses. For initial assessment of
dose response, single dose administration is appropriate,
however these findings should be confirmed.
Clinical benefits will require chronic-dosing that must
be evaluated in appropriately designed longer-term stu-
dies. Finally, the relatively small sample size precludes
many comparisons with the active comparator and pro-
vides limited information about associated rare events.
Conclusions
This study was designed to evaluate the efficacy and safety
of 4 doses of GP MDI so that the dose(s) that produce a
consistent 12- and/or 24-hour duration of action can be
selected for more definitive studies (phase 2b/phase 3).
Glycopyrronium MDI 14.4, 28.8, 57.6, and 115.2 μg de-
monstrated statistically significant and clinically relevant
superior bronchodilator efficacy compared with Placebo
MDI in study patients with mild to moderate COPD. The
overall profile of GP MDI based on 12-hr post-dose FEV1
compared with 24-hr post-dose tFEV1, and AUC0–12 com-
pared with AUC12–24 support a BID dosing regimen at all
doses evaluated. These same comparisons confirmed TIO
as a QD drug. Based on the results of the current study,
the candidate doses of GP MDI for further evaluation
were total daily doses of 57.6 or 115.2 μg, administered as
28.8 or 57.6 μg given BID.
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